
Sundry Income (Expense) - Net
(In millions) For the years ended December 31,	2025		2024		2023
Non-operating pension and other post-employment benefit ("OPEB") credits (costs)	$	5	$	9	$	(13)
Interest income 1, 2	98		74		155
Net gain on divestiture and sales of other assets and investments 3	3		4		11
Foreign exchange losses, net	(34)		(3)		(77)
Loss on debt extinguishment 4	(114)		(74)		—
Interest rate swap mark-to-market gain (loss) 5	31		(138)		—

Miscellaneous income (expenses) - net 6	25		17		4
Sundry income (expense) - net	$	14	$	(111)	$	80

1.The years ended December 31, 2025 and 2024 include non-cash interest income of $27 million and $26 million, respectively, related to the $350 million Delrin® related party note receivable. Refer to Note 4 for additional information.

2.The year ended December 31, 2023 includes interest on cash and marketable securities. Fluctuations in interest income are due to changes in cash balances and/or changes in interest rates.

3.The year ended December 31, 2023 primarily reflects income related to a land sale within the Diversified Industrials segment and gain adjustments from previously divested businesses.

4.The year ended December 31, 2025 includes $15 million of treasury transaction-related fees in addition to $99 million loss on debt extinguishment related to the Debt Exchange, Special Mandatory Redemption, Consent Solicitation and Tender Offer. The year ended December 31, 2024 reflects the loss on the partial redemption of an aggregate principal amount of the 2038 Notes. Refer to Note 15 for further details.

5.The year ended December 31, 2025, reflects the non-cash mark-to-market net gain related to the 2022 Swaps and 2024 Swaps offset by the interest settlement loss on the 2022 Swaps, while the year ended December 31, 2024, reflects non-cash mark-to-market loss related to the 2022 Swaps and 2024 Swaps and the interest settlement loss on the 2022 Swaps. Refer to Note 21 for further details.

6.The year ended December 31, 2025 includes a benefit related to adjustments of the Donatelle contingent earn-out liability. Refer to Note 3 for further details.

At December 31, 2025 and 2024, the Company had "Cash and cash equivalents" in the Consolidated Balance Sheets of $715 million and $1,792 million, respectively.

At December 31, 2025 and 2024, the Company had restricted cash of $42 million and $6 million, respectively, within “Restricted cash and cash equivalents” in the Consolidated Balance Sheets, of which $37 million of the balance at December 31, 2025 is attributable to the MOU cost sharing arrangement. Additional information can be found in Note 16.

At December 31, 2025 and 2024, the Company had zero and $36 million, respectively, within "Restricted cash and cash equivalents - noncurrent" in the Consolidated Balance Sheets. The balance during 2024 is attributable to the MOU cost sharing arrangement.

Within discontinued operations related to the Aramids Divestiture and the Electronics Separation the Company has $3 million and $58 million within "Cash and cash equivalents" at December 31, 2025 and 2024, respectively. Additional information can be found in Note 4.

"Accrued and other current liabilities" in the Consolidated Balance Sheets were $882 million at December 31, 2025 and $784 million at December 31, 2024. Accrued payroll, which is a component of "Accrued and other current liabilities" was $238 million at December 31, 2025 and $228 million at December 31, 2024. At December 31, 2025 and December 31, 2024 the balance includes approximately $323 million and $167 million related to accrued indemnified current liabilities associated with the Electronics Separation, MOU and environmental obligations further discussed in Note 4 and Note 16. No other component of "Accrued and other current liabilities" was more than five percent of total current liabilities at December 31, 2025 and 2024.